The emerging low-dose therapy for advanced cancers

Dose-Response

Volumn 7, Issue 3, 2009, Pages 208-220

  Satti, Jahangir ^a  

^a ALBANY MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Homeopathy; Hormesis; Low dose; Metronomic

Indexed keywords

EID: 70349565677     PISSN: None     EISSN: 15593258     Source Type: Journal    
DOI: 10.2203/dose-response.08-010.satti     Document Type: Article

References (71)

1. Adjei AA. 2006. What is the right dose? The elusive optimal biologic dose in phase I clinical trials. Journal of Clinical Oncology 24(25):4054-4055.
2. Agutter PS. 2007. Cell mechanics and stress: from molecular details to the "universal cell reaction" and hormesis. BioEssays 29:324-333.
3. Baruchel S and Stempak D, 2006. Low-dose metronomic chemotherapy: Myth or Truth? Onkologie. 29:305-307.
4. Barajas-Farias LM, Pérez-Carreón JI, Arce-Popoca E, Fattel-Fazenda S, Alemán-Lazarini L, Hernández-García S, Salcido-Neyoy M, Cruz-Jiménez FG, Camacho J, Villa-Treviño S. 2006. A dual and opposite effect of calendula officinalis flower extract: chemoprotector and promoter in rat hepatocarcinogenesis model, Planta Med;72:217-221.
5. Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y, Kerbel RS. 2003. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Research 63:4342-4346.
6. Bocci G, Nicolaou KC, Kerbel RS. 2002. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Research 62:6938-6943.
7. Bocci G, Tuccori M, Emmenegger U, Liguori V, Falcone A, Kerbel RS, and Del Tacca M. 2005. Cyclophosphamide-methotrexate "metronomic" chemotherapy for the palliative treatment of metastatic cancer. A comparative pharmacoeconomic evaluation. Ann Oncol 16:1243-1252.
8. Bosanquet N, Sikora K. 2004. The economics of cancer care in the UK. Lancet Oncol 5:568-574.
9. Brower V. 2003. Less is more. EMBO 4(9):831-834.
10. Calabrese EJ, Baldwin LA. 1998. Hormesis as a biological hypothesis. Environ Health Perspect 106(Suppl 1):357-362.
11. Calabrese EJ, 2004. Paradigm lost, paradigm found: The re-emergence of hormesis as a fundamental dose response model in the toxicological sciences. Environmental Pollution. 138:378-411
12. Calabrese EJ, and Blain R. 2005. The occurrence of hormetic dose responses in the toxicological literature, the hormesis database: an overview, Toxicology and Applied Pharmacology 202:289-301.
13. Calabrese EJ, Bachmann KA, Bailer AJ, Bolger PM, Borak J, Cai L, Cedergreen N, Cherian MG, Chiueh CC, Clarkson TW, Cook RR, Diamond DD, Doolittle DJ, Dorato MA, Duke SO, Feinendegen L, Gardner DE, Hart RW, Hastings KL, Hayes AW, Hoffmann GR, Ives JA, Jaworowski Z, Johnson TE, Jonas WB, Kaminski NE, Keller JG, Klaunig JE, Knudsen TB, Kozumbo WJ, Lettieri T, Liu S-Z, Maisseu A, Maynard KI, Masoro EJ, McClellan RO, Mehendale HM, Mothersill C, Newlin D, Nigg HN, Oehme FW, Phalen RF, Philbert MA, Rattan SIS, Riviere JE, Rodricks J, Sapolsky RM, Scott BR, Seymour C, Sinclair DA, Smith-Sonneborn J, Snow ET, Spear L, Stevenson DE, Thomas Y, Tubiana M, Williams GM, Mattson MP. 2007. Biological stress response terminology: Integrating the concepts of adaptive response and preconditioning stress within a hormetic dose-response framework. Toxicol. Appl. Pharmacol. 222(1):122-128.
14. Calabrese EJ. 2007. Threshold-dose-response model-RIP: 1911 to 2006. Bioessays 29:686-688.
15. Cameron JR and Moulder JE, 1998. Proposition: Radiation hormesis should be elevated to a position of scientific respectability. Medical Physics. 25(8).1407-1410.
16. Chen WL, Luan YC, Shieh MC, Chen ST, Kung HT, Soong KL, Yeh YC, Chou TS, Mong SH, Wu JT, Sun CP, Deng WP, Wu MF, Shen ML. 2006. Effects of cobalt-60 exposure on the health of Taiwan residents suggest new approach needed in radiation protection. Dose Response. 5(1):63-75.
17. Chirikos TN. 2002. Cancer economics: on variations in the costs of treating cancer. Cancer Control 9:59-66.
18. Colleoni M, Gelber S, and Goldhirsch A. 2005. Treatment of advanced breast cancer: the good, the bad and the ugly. Ann Oncol 16:1219-1221.
19. Colleoni M, Orlando L, Sanna G, Rocca A, Maisonneuve P, Peruzzotti G, Ghisini R, Sandri MT, Zorzino L, Nole F, Viale G and Goldhirsch A. 2006. Metronomic low-dose oral cyclophos-phamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects, Annals of Oncology 17:232-238.
20. Curry III TS, Dowdey JE, and Murry Jr. RC. 1990. Christensen's Physics of Diagnostic Radiology. Williams & Wilkins, Baltimore, USA.
21. Cuttler JM. 2007. Health effects of low level radiation: when will we acknowledge the reality? Dose-Response 5:292-298.
22. Davies J, Spiegelman GB, and Yin G. 2006. The world of subinhibitaroy antibiotic concentrations. Current Opnion in microbiology. 9:445-453.
23. De Pas T, Colleoni M, Orlando L, Masci G, Rocca A, Catania C, Curigliano G, Manzoni S, Goldhirsch A, and de Braud F. 2005. Reply to the article "Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity" by V. R. Rozados et al. Ann Oncol 2004;15: 543-1550)
24. ... and in humans? Annals of Oncology 16: 673-677.
25. duManoir JM, Francia G, Man S, Mossoba M, Medin JA, Viloria-Petit A, Hicklin DJ, Emmenegger U, Kerbel RS. 2006. Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. Clin Cancer Res 12(3):904-916.
26. Emmenegger U, Man S, Shaked Y, Francia G, Wong JW, Hicklin DJ, Kerbel RS. 2004. A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens. Cancer Research 64:3994-4000.
27. Folkman J. 2003. Fundamental concepts of the angiogenic process. Current Molecular Medicine 3:643-651.
28. Franchi F, Grassi P, Ferro D, Pigliucci G, De Chicchis M, Castigliani G, Pastore C, and Seminara P. 2007. Antiangiogenic metronomic chemotherapy and hyperthermia in the palliation of advanced cancer. European Journal of Cancer Care 16:258-262.
29. Fukai Y, Hirata M, Ueno M, Ichikawa N, Kobayashi H, Saitoh H, Sakurai T, Kinoshita K, Kaise T, Ohta S., 2006. Clinical pharmacokinetic study of arsenic trioxide in an acute promyelocytic leukemia (APL) patient: speciation of arsenic metabolites in serum and urine. Biol Pharm Bull. May;29(5):1022-1027.
30. Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, Roman L, Groshen S, Swenson S, Markland F, Gandara D, Scudder S, Morgan R, Chen H, Lenz HJ, Oza AM. 2008. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia, J Clin Oncol 26:76-82.
31. Gasparini G. 1997. Antiangiogenic drugs as a novel anticancer therapeutic strategy Which are the more promising agents? What are the clinical developments and indications? Critical Reviews in Oncology: Hematology 26:147-162.
32. Gasparini G. 2001. Metronomic scheduling: the future of chemotherapy? Lancet Oncol; 2:733-740.
33. Hanahan D, Bergers G, and Bergsland E. 2000. Less is more, regularly: metronomic dosing of cyto-toxic drugs can target tumor angiogenesis in mice. The Journal of Clinical Investigation 105(8):1045-1047.
34. Jiménez-Medina E, Garcia-Lora A, Paco L, Algarra I, Collado A, Garrido F. 2006. A new extract of the plant Calendula officinalis produces a dual in vitro effect: cytotoxic anti-tumor activity and lymphocyte activation. BMC Cancer. 5:1-14.
35. Kamat AA, Kim TJ, Landen CN Jr., Lu C, Han LY, Lin YG, Merritt WM, Thaker PH, Gershenson DM, Bischoff FZ, Heymach JV, Jaffe RB, Coleman RL, Sood AK. 2007. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res. 67(1):281-288.
36. Kamen BA, Glod J, Cole PD. 2006. Metronomic therapy from a pharmacologist's view. J Pediatr Hematol Oncol 28(6):325-327.
37. Kamen BA, Rubin E, Aisner J, and Glatstein E. 2000. High-time chemotherapy or high time for low dose. Journal of Clinical Oncology 18(16):2935-2937.
38. Kamen BA. 2005. Metronomic therapy it makes sense and is patient friendly. J Pediatr Hematol Oncol. 27:571-572.
39. Kerbel RS, Klement G, Prithard KI and Kamen B. 2002. Continuous low-dose antiangiogenic metronomic chemotherapy: from the research laboratory into the oncology clinic. Annals of Oncology 13:12-15.
40. Kinoshita A, Wanibauchi H, Wei M, and Fukushima S. 2006. Hormesis in carcinogenicity of non-genotoxic carcinogens. J Toxicol Pathol 19:111-122.
41. Lam T, Hetherington JW, Greenman J, and Maraveyas A. 2006. From total empiricism to a rational design of metronomic chemotherapy phase I dosing trials, Anti-Cancer Drugs 17:113-121.
42. Liu B, Pan S, Dong X, Qiao H, Jiang H, Krissansen GW and Sun X. 2006. Opposing effects of arsenic trioxide on hepatocellular carcinomas in mice. Cancer Sci. 97:675-681.
43. Lutz WK, Gaylor DW, Conolly RB, Lutz RW. 2005. Nonlinearity and thresholds in dose-response relationships for carcinogenicity due to sampling variation, logarithmic dose scaling, or small differences in individual susceptibility. Toxicology and Applied Pharmacology 207:S565 - S569.
44. Ma L, Francia G, Viloria-Petit A, Hicklin DJ, du Manoir J, Rak J, Kerbel RS. 2005. In vitro proco-agulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy. Cancer Res 65(12):5365-5373.
45. Macklis RM and Beresford B. 1991. Radiation hormesis. The J of Nuclear Medicine. 32(2):350-359.
46. Man S, Bocci G, Francia G, Green SK, Jothy S, Hanahan D, Bohlen P, Hicklin DJ, Bergers G, Kerbel RS. 2002. Antitumor effects in mice of low-dose (Metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Research. 62:2731-2735.
47. Mancuso P, Colleoni M, Calleri A, Orlando L, Maisonneuve P, Pruneri G, Agliano A, Goldhirsch A, Shaked Y, Kerbel RS, and Bertolini F. 2006. Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy, Blood 108:452-459.
48. Maraveyas A, Lam T, Hetherington JW, and Greenman J. 2005. Letter to the Editor: Can a rational design for metronomic chemotherapy dosing be devised? British Journal of Cancer 92:1588-1590.
49. Mattson MP, and Cheng A. 2006. Neurohormetic phytochemicals: low-dose toxins that induce adaptive neuronal stress responses. Trends in Neurosciences 29(11):632-639.
50. Miller KD. 2004. Commentary: Recent translational research: antiangiogenic therapy for breast cancer - where do we stand? Breast Cancer Res 6:128-132.
51. Munoz R, Man S, Shaked Y, Lee CR, Wong J, Francia G, Kerbel RS. 2006 Highly efficacious non-toxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT cyclophosphamide metronomic chemotherapy. Cancer Res 66(7):3386-3391.
52. Munoz R, Shakeda Y, Bertolinic F, Emmeneggera U, Mana S, Kerbel RS. 2005. Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy, The Breast. 14:466-479.
53. Mushak P. 2007. Hormesis and its place in non monotonic dose-response relationship: some scientific reality checks. Environ Health Prespect. 115:500-506.
54. Piccart-Gebhart MJ. 2003. Mathematics and oncology: A match for life? Journal of Clinical Oncology 21(8):1425-1428.
55. Rost EC., 2008. The medical community must investigate broader use of positron emission tomography to maximize its treatment-planning capabilities. Enterprise Imaging and Therapeutic Radiology Management 18(3):44-47.
56. Rozados VR, Sanchez AM, Gervasoni SI, Berra HH, Matar P, Scharovsky OG. 2004. Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity. Annals of Oncology 15:1543-1550.
57. Rylander R. 2004. Noise, stress and annoyance. J Sound Vibr 277:471-478.
58. Satti, JA. 2005. Homeopathic Drug Standardization. Semin Integr Med 3(4):113-122.
59. Shaked Y, Emmenegger U, Francia G, Chen L, Lee CR, Man S, Paraghamian A, Ben-David Y, Kerbel RS. 2005a. Low-dose metronomic combined with intermittent bolus dose cyclophos-phamide is an effective long-term chemotherapy treatment strategy. Cancer Res 65(16):7045-7051.
60. Shaked Y, Emmenegger U, Man S, Cervi D, Bertolini F, Ben-David Y, Kerbel RS. 2005b. Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangio-genic activity. Blood 106:3058-3061.
61. Shimizu K and Oku N. 2004. Cancer anti-angiogenic therapy. Biol. Pharm. Bull. 27(5):599-605.
62. Snow ET, Sykora P, Durham TR, Klein CB. 2005. Arsenic, mode of action at biologically plausible low doses: What are the implications for low dose cancer risk? Toxicology and Applied Pharmacology 207:S557 - S564.
63. Soucy NV, Ihnat MA, Kamat CD, Hess L, Post MJ, Klei LR, Clark C, and Barchowsky A. 2003. Arsenic stimulates angiogenesis and tumorigenesis in vivo. Toxicological Sciences 76:271-279.
64. Stumpf WE. 2006. The dose makes the medicine. Drug Discoy Today 11(11-12):550-555.
65. Tassinari D, Poggi B, Fantini M, Tamburini E, Nicoletti S and Sartori S. 2006. Cost- opportunity analysis in clinical oncology: from the "wild far-west" to a correct integration of the disciplines, avoiding the "war of the worlds" letters to the editor 17(5):876-877.
66. Thayer KA, Melnick R, Burns K, Davis D, and Huff J. 2005. Fundamental flaws of hormesis for public health decisions. Environ Health Perspect 113:1271-1276.
67. Walchli D, Baumgartner S, and Bastide M. 2006. Effects of low doses and high homeopathic potencies in normal and cancerous human lymphocytes: An in vitro isopathic study. The Journal of Alternative and Complementary Medicine 12(5):421-427.
68. WHO 2008. http://www.who.int/dietphysicalactivity/publications/facts/ chronic/en/ (accessed on June 17, 2008)
69. Yap R, Veliceasa D, Emmenegger U, Kerbel RS, McKay LM, Henkin J, Volpert OV. 2005. Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: A complementation antiangiogenic strategy. Clin Cancer Res 11(18):6678-6685.
70. Young SD, Whissell M, Noble JCS, Cano PO, Lopez PG, Germond CJ. 2006. Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors. Clin Cancer Res 12(10):3090-3098.
71. Yun AJ, Lee PY, Bazar KA. 2005. Paradoxical strategy for treating chronic diseases where the therapeutic effect is derived from compensatory response rather than drug effect. Medical Hypotheses 64:1050-1059.